Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 9
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
MET exon 14 skipping
ovarian cancer · Monoclonal Antibody
MET exon 14 skipping is flagged as trial selection rising because public trials show inclusion required evidence in 9 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 1
Common snippets: DMMR
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT04870177 | https://clinicaltrials.gov/study/NCT07314619 | https://clinicaltrials.gov/study/NCT07002346 | https://clinicaltrials.gov/study/NCT02764333 | https://clinicaltrials.gov/study/NCT05613088 | https://clinicaltrials.gov/study/NCT05200364 | https://clinicaltrials.gov/study/NCT03748186 | https://clinicaltrials.gov/study/NCT06890338 | https://clinicaltrials.gov/study/NCT06682988